-
PH Patients Prefer Yutrepia Over Tyvaso in INSPIRE Study
Yutrepia, an inhaled formulation of treprostinil, was generally well tolerated and improved the quality of life for people with PH in the Phase 3 INSPIRE clinical trial.
Here are some of the highlights from this exciting article.
*The dry powder form of treprostinil.
*Safety, dosing, and tolerability confirmed
*Convenient
*Frequency of side effects markedly lower in those who switched from Tyvaso
*Final decision for FDA approval later this yearYou can read more here.
It’s always inspiring to read about promising clinical trials and improving the quality of life for those within the PH community. Do you have any takeaways from this article?
-
0 Replies
Sorry, there were no replies found.
Log in to reply.